about
Losigamone add-on therapy for partial epilepsyLosigamone add-on therapy for partial epilepsyLosigamone add-on therapy for partial epilepsyManagement of epilepsy in womenCannabinoids and Epilepsy.Managing drug-resistant epilepsy: challenges and solutionsGrafts of adenosine-releasing cells suppress seizures in kindling epilepsyEvolution and prospects for intracranial pharmacotherapy for refractory epilepsies: the subdural hybrid neuroprosthesis.Evaluation of machine learning algorithms for treatment outcome prediction in patients with epilepsy based on structural connectome data.Approach to the patient with epilepsy in the outpatient department.Syncope in patients with drug-resistant epilepsy without apparent cardiovascular disease.Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug DevelopmentAntiepileptic drug treatment: outcomes and adherence.Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy.Levetiracetam: a novel antiepileptic drug.The frequency and precipitating factors for breakthrough seizures among patients with epilepsy in UgandaComparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: systematic review and network meta-analysis reveals the need for long term comparator trialsAdvancing the medical management of epilepsy: disease modification and pharmacogenetics.Adherence to medication among outpatient adolescents with epilepsy.Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsyCentral nervous system lupus: a clinical approach to therapy.Comprehensive care of the epilepsy patient--control, comorbidity, and cost.Evaluation of the Effects of Charged Amino Acids on Uncontrolled Seizures.Therapeutic drug monitoring of old and newer anti-epileptic drugs.Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies.Perspectives of adults with epilepsy and their support persons on self-management supportDiagnosing refractory epilepsy: response to sequential treatment schedules.Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications.Overview: definitions and classifications of seizure emergencies.Antisense reduction of tau in adult mice protects against seizuresBrain tumors and epilepsy.Clinical and electroencephalographic characteristics of a cohort of patients with epilepsy and absence seizures.Adjunctive antiepileptic drugs in adult epilepsy: how the first add-on could be the last.Seizures and the natural history of World Health Organization Grade II gliomas: a review.Alternative surgical approaches in epilepsy.Drug resistance in epilepsy and the ABCB1 gene: The clinical perspective.The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs.Complex metabolically demanding sensory processing in the olfactory system: implications for epilepsy.Migraine and epilepsy: review of the literature.Clinico-Electroencephalography Pattern and Determinant of 2-year Seizure Control in Patients with Complex Partial Seizure Disorder in Kano, Northwestern Nigeria.
P2860
Q24187144-AA40EBD9-4919-44CC-B324-AD24BDDBC75DQ24202674-A48BF6A4-4C9A-406E-84E9-CE711A672464Q24234741-C8157F1B-7CBD-4DB4-8E5F-0133C14FAF43Q24680158-F68B6841-D043-488B-81A0-9EE49A54C95EQ27336451-8C35FD29-870F-4D57-9601-7F61AB43F059Q28066264-B9ADE596-6CC2-4831-B82E-EC5CCB55E7BCQ28366761-49376C42-8E9F-492C-AAE0-9328D784EDB5Q30464364-4AA1CFAF-965C-4536-A3E5-C8B9CE28CFBEQ30967973-FF77F68E-65C2-4B31-9B37-25B3938DF29BQ30993569-5A7134A3-E93A-4178-B337-42DAF0C329E7Q33163635-D8975912-499E-4CC6-B1DA-E9314A38A2C6Q33677979-2A7BAEA6-F430-43BD-8C38-EC4F2C7685F9Q33999491-11EBCA48-D931-49E6-AF54-DF766E68E921Q34090573-682A9B01-503F-4A08-BFE7-9DAC24EA4DD2Q34443362-4B4A9948-9D43-4496-B006-8704C11EDF66Q34465308-C012860B-BA60-4D25-9483-77745375D0EBQ34563933-37543C9A-BDDC-47E4-A01C-6C8CD6E94435Q34579490-CDDC50EB-AEAD-49AD-97AB-8CC871B8E1FAQ35028736-581596A0-8567-4D6C-A031-CF211DE7E76CQ35617456-1A722938-25E4-4CA9-B103-66A9E41FB461Q35625240-9B843993-BC70-4E18-9652-B9326535499DQ35865168-0A95A277-8507-48D2-B515-818BB17B498BQ35882451-CBDA0589-34AD-4C5C-8AE5-1F2F65ED142AQ35970354-7C789E34-704B-4204-B002-F853F5AD4C70Q35999731-F437EF64-E6E4-4229-9C51-D35DB622A60BQ36216513-037C01CC-8408-4E8A-B7B8-CB80D6FFC802Q36450747-AFC3C2E1-1D33-4894-9C8A-D2BA49D37FDCQ36555922-91425E94-7DC3-4C31-838E-37E3216E1F20Q36906470-04C38973-B62E-4DEC-B255-631033AEC177Q37058143-2D6EFF1B-D3FA-46A4-A1DB-E6A07CA62CFCQ37174060-9ED37E33-1730-4F21-9831-F1A6CCDE0BE2Q37673001-4E64D917-2130-4B2A-82BC-72FF3659447FQ37733552-DDCB3272-9986-4A47-986A-40564F673FA2Q37838691-1C573787-8D4B-4CC4-9CDD-7F99AC29A0AAQ37876338-07599FB6-2CDB-4C7E-B457-8786788D9F40Q37900131-C89ACFA0-2439-4336-8556-5BAFE40DEC0BQ38104378-204A6846-AFCD-418F-9EEB-ECAB53630FDEQ38151430-9B8D1BE7-8164-4E03-BB15-78933A7993E1Q38371291-D6469380-7765-4A6E-88E9-24F4C57F2949Q38831296-F5368C05-A362-4B5D-A353-FD42A41022EB
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Patients with refractory seizures.
@ast
Patients with refractory seizures.
@en
type
label
Patients with refractory seizures.
@ast
Patients with refractory seizures.
@en
prefLabel
Patients with refractory seizures.
@ast
Patients with refractory seizures.
@en
P1476
Patients with refractory seizures
@en
P2093
Devinsky O
P304
P356
10.1056/NEJM199905203402008
P407
P577
1999-05-01T00:00:00Z